Opal Capital’s Nurix Therapeutics NRIX Stock Holding History

Opal Capital’s Portfolio NRIX Stock Details NRIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-12,078	Closed	-$202K	–	196
2025 Q4	$202K	Buy	+12,078	New	+$174K	0.05%	181

Other funds holding NRIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return

Opal Capital's NRIX Position: Q1 2026 in Review

Opal Capital sold out of Nurix Therapeutics (NRIX) in Q1 2026, closing a stake of 12,078 shares — an estimated $202K sold.

Opal Capital first reported a position in NRIX in Q4 2025 and held it in 1 quarter. The position peaked at $202K in Q4 2025. 196 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

Opal Capital reported no remaining Nurix Therapeutics position as of Q1 2026 after selling out during the quarter.
Opal Capital sold 12,078 Nurix Therapeutics shares in Q1 2026, an estimated $202K.
Opal Capital first reported a position in Nurix Therapeutics in Q4 2025 and held it in 1 quarter.
Opal Capital's Nurix Therapeutics position peaked at $202K in Q4 2025.
196 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Opal Capital's 13F filing for Q1 2026, filed 18 May 2026.